Share on facebook
Share on twitter
Share on linkedin
Share on telegram
Share on whatsapp

Feds Pause COVID-19 Authorized Monoclonal Antibody Treatment in 8 States Over Potential Failure Against BA.2 Omicron Subvariant

The federal government is sharply pulling back on one of the monoclonal antibody treatments authorized for COVID-19, pausing its use across eight states out of concerns it could fail against the BA.2 omicron subvariant.

The therapy, called Sotrovimab from GlaxoSmithKline and Vir Biotechnology, is now no longer authorized by the FDA in Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey and New York, as well as Puerto Rico and the Virgin Islands, while BA.2 is the prevailing variant of SARS-CoV-2, the agency announced Friday (March 25).

In those impacted areas, BA.2 is estimated to account for more than 50% of new COVID-19 cases as of March 19, according to data from the CDC.

Distribution of the drug will now be “immediately” paused across those regions, the Department of Health and Human Services said.

    Joe Biden: Pandemic is Over

    Joe Biden during an interview on 60Minutes says he believes the COVID pandemic is Over. 850 more unvaxxed NYC teachers, aides fired for not complying

    Lockdowns Harms Impossible to Cover Up

    “According to a recent study by the World Bank, published in the journal Nature, lockdowns and the response to Covid-19 have pushed an additional 75

    Contagious Vaccines: A Warning

    Brownstone Institute – For two decades scientists have been quietly developing self-spreading contagious vaccines. The NIH funded this research, in which either DNA from a deadly

    VAERS Reports as of 6/10/2022 Release

    28,859 Deaths where Vaccine is COVID19 1,301,356 Adverse Events where Vaccine is COVID19 Search Vaccine Reactions Using MedAlertsA Powerful VAERS Database Search Engine hosted by

    Would love your thoughts, please comment.x

    Get in Touch!

    Purpose of your Contact
    Where can i reach you?
    What would you like to discuss?

    Are you intending to visit the Lorphic marketing agency?